Key clinical point: Magrolimab plus azactydine (AZA) improved outcomes in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients.
Major finding: Magrolimab/AZA induced a 91% overall response rate in MDS patients and a 64% ORR in AML patients.
Study details: A phase 1b study of 29 untreated AML patients and 39 untreated MDS patients who received magrolimab plus AZA.
Disclosures: The trial was sponsored by Gilead Sciences, and funding was obtained from the California Institute for Regenerative Medicine. Dr. Sallman disclosed that he received research funding from Celgene and has acted in a consulting or advisory role for Agios; argenx; and Celyad. He was also on the speaker’s bureau for a variety of pharmaceutical/biotech companies.
Sallman DA et al. ASCO 2020. EHA25. Abstract 7507.